FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093018651> ?p ?o ?g. }

• W3093018651 endingPage "884" @default.
• W3093018651 startingPage "871" @default.
• W3093018651 abstract "We investigated whether microRNA-150 (miR-150)-based RNA interference (RNAi) ameliorates tubular injury and tubulointerstitial fibrosis. Mice injected with folic acid developed tubulointerstitial fibrosis at day 30. miR-150 levels were increased at day 7 and peaked at day 30. At day 30, protein levels of α-smooth muscle actin, fibronectin (FN), and collagen 1 (COL-1) were increased, while suppressor of cytokine signal 1 (SOCS1) was decreased. Kidneys manifested increased macrophage numbers and increased expression of potential mediators: interferon-γ, interleukin-6, and tumor necrosis factor-α. Locked nucleic acid-anti-miR-150, started prior to or after tubular injury and administered twice weekly for 4 weeks, reversed renal inflammation and fibrosis. In HK-2 cells, co-culture with macrophages increased miR-150 expression and decreased SOCS1. Janus kinase (JAK) and signal transducer and activators of transcription (STAT) pathway-related proteins p-JAK1, p-JAK2, p-STAT1, p-STAT3, and pro-fibrotic genes encoding α-smooth muscle actin, FN, and COL-1 were all upregulated. The miR-150 antagonist reversed these transcriptional changes. Lastly, in renal biopsies from patients with chronic interstitial fibrosis, renal miR-150, and pro-fibrotic gene expression and macrophage numbers were increased, while SOCS1 expression was decreased. In conclusion, miR-150-based RNAi is as a potential novel therapeutic agent for tubulointerstitial fibrosis, suppressing the SOCS1/JAK/STAT pathway and reducing macrophage influx. We investigated whether microRNA-150 (miR-150)-based RNA interference (RNAi) ameliorates tubular injury and tubulointerstitial fibrosis. Mice injected with folic acid developed tubulointerstitial fibrosis at day 30. miR-150 levels were increased at day 7 and peaked at day 30. At day 30, protein levels of α-smooth muscle actin, fibronectin (FN), and collagen 1 (COL-1) were increased, while suppressor of cytokine signal 1 (SOCS1) was decreased. Kidneys manifested increased macrophage numbers and increased expression of potential mediators: interferon-γ, interleukin-6, and tumor necrosis factor-α. Locked nucleic acid-anti-miR-150, started prior to or after tubular injury and administered twice weekly for 4 weeks, reversed renal inflammation and fibrosis. In HK-2 cells, co-culture with macrophages increased miR-150 expression and decreased SOCS1. Janus kinase (JAK) and signal transducer and activators of transcription (STAT) pathway-related proteins p-JAK1, p-JAK2, p-STAT1, p-STAT3, and pro-fibrotic genes encoding α-smooth muscle actin, FN, and COL-1 were all upregulated. The miR-150 antagonist reversed these transcriptional changes. Lastly, in renal biopsies from patients with chronic interstitial fibrosis, renal miR-150, and pro-fibrotic gene expression and macrophage numbers were increased, while SOCS1 expression was decreased. In conclusion, miR-150-based RNAi is as a potential novel therapeutic agent for tubulointerstitial fibrosis, suppressing the SOCS1/JAK/STAT pathway and reducing macrophage influx." @default.
• W3093018651 created "2020-10-22" @default.
• W3093018651 creator A5006012404 @default.
• W3093018651 creator A5017395810 @default.
• W3093018651 creator A5017658063 @default.
• W3093018651 creator A5029732076 @default.
• W3093018651 creator A5030526891 @default.
• W3093018651 creator A5032147441 @default.
• W3093018651 creator A5036817167 @default.
• W3093018651 creator A5041034509 @default.
• W3093018651 creator A5044494633 @default.
• W3093018651 creator A5068514271 @default.
• W3093018651 creator A5072641478 @default.
• W3093018651 creator A5080434445 @default.
• W3093018651 creator A5082540496 @default.
• W3093018651 date "2020-12-01" @default.
• W3093018651 modified "2023-10-18" @default.
• W3093018651 title "miR-150-Based RNA Interference Attenuates Tubulointerstitial Fibrosis through the SOCS1/JAK/STAT Pathway In Vivo and In Vitro" @default.
• W3093018651 cites W1150566944 @default.
• W3093018651 cites W1549131701 @default.
• W3093018651 cites W1977697731 @default.
• W3093018651 cites W1979456680 @default.
• W3093018651 cites W1985436679 @default.
• W3093018651 cites W1995122286 @default.
• W3093018651 cites W2022617421 @default.
• W3093018651 cites W2024704386 @default.
• W3093018651 cites W2059061787 @default.
• W3093018651 cites W2085877951 @default.
• W3093018651 cites W2097628596 @default.
• W3093018651 cites W2104212366 @default.
• W3093018651 cites W2134211155 @default.
• W3093018651 cites W2145979480 @default.
• W3093018651 cites W2163687584 @default.
• W3093018651 cites W2171202584 @default.
• W3093018651 cites W2195107264 @default.
• W3093018651 cites W2203566365 @default.
• W3093018651 cites W2256903816 @default.
• W3093018651 cites W2257544965 @default.
• W3093018651 cites W2323645949 @default.
• W3093018651 cites W2405319291 @default.
• W3093018651 cites W2408996411 @default.
• W3093018651 cites W2477226701 @default.
• W3093018651 cites W2752807449 @default.
• W3093018651 cites W2755151001 @default.
• W3093018651 cites W2766858075 @default.
• W3093018651 cites W2767501672 @default.
• W3093018651 cites W2793714353 @default.
• W3093018651 cites W2809667088 @default.
• W3093018651 cites W2908462368 @default.
• W3093018651 cites W2913590717 @default.
• W3093018651 cites W2920438880 @default.
• W3093018651 cites W2944372605 @default.
• W3093018651 cites W2944919517 @default.
• W3093018651 cites W2977682063 @default.
• W3093018651 cites W2991545250 @default.
• W3093018651 cites W2996443756 @default.
• W3093018651 cites W3000595341 @default.
• W3093018651 cites W3004081420 @default.
• W3093018651 cites W3016622249 @default.
• W3093018651 cites W3017100357 @default.
• W3093018651 doi "https://doi.org/10.1016/j.omtn.2020.10.008" @default.
• W3093018651 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7658580" @default.
• W3093018651 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33230482" @default.
• W3093018651 hasPublicationYear "2020" @default.
• W3093018651 type Work @default.
• W3093018651 sameAs 3093018651 @default.
• W3093018651 citedByCount "27" @default.
• W3093018651 countsByYear W30930186512021 @default.
• W3093018651 countsByYear W30930186512022 @default.
• W3093018651 countsByYear W30930186512023 @default.
• W3093018651 crossrefType "journal-article" @default.
• W3093018651 hasAuthorship W3093018651A5006012404 @default.
• W3093018651 hasAuthorship W3093018651A5017395810 @default.
• W3093018651 hasAuthorship W3093018651A5017658063 @default.
• W3093018651 hasAuthorship W3093018651A5029732076 @default.
• W3093018651 hasAuthorship W3093018651A5030526891 @default.
• W3093018651 hasAuthorship W3093018651A5032147441 @default.
• W3093018651 hasAuthorship W3093018651A5036817167 @default.
• W3093018651 hasAuthorship W3093018651A5041034509 @default.
• W3093018651 hasAuthorship W3093018651A5044494633 @default.
• W3093018651 hasAuthorship W3093018651A5068514271 @default.
• W3093018651 hasAuthorship W3093018651A5072641478 @default.
• W3093018651 hasAuthorship W3093018651A5080434445 @default.
• W3093018651 hasAuthorship W3093018651A5082540496 @default.
• W3093018651 hasBestOaLocation W30930186511 @default.
• W3093018651 hasConcept C104317684 @default.
• W3093018651 hasConcept C112392421 @default.
• W3093018651 hasConcept C121608353 @default.
• W3093018651 hasConcept C126322002 @default.
• W3093018651 hasConcept C14077384 @default.
• W3093018651 hasConcept C145059251 @default.
• W3093018651 hasConcept C157333092 @default.
• W3093018651 hasConcept C166703698 @default.
• W3093018651 hasConcept C171958077 @default.
• W3093018651 hasConcept C179185449 @default.
• W3093018651 hasConcept C185592680 @default.
• W3093018651 hasConcept C2778690821 @default.
• W3093018651 hasConcept C2778923194 @default.

• next